Last updated: February 19, 2026
This report provides a detailed analysis of Canadian patent CA2728408, focusing on its scope, key claims, and the broader patent landscape surrounding the covered pharmaceutical subject matter. This patent, related to the drug vortioxetine, is assigned to Lundbeck (H. Lundbeck A/S).
What is the Subject Matter Protected by CA2728408?
Canadian patent CA2728408 covers specific crystalline forms of vortioxetine hydrobromide. Vortioxetine is a multimodal antidepressant developed by Lundbeck and Takeda Pharmaceuticals. The patent specifically addresses crystalline forms that offer advantages in terms of stability and/or manufacturing.
What are the Key Claims of CA2728408?
The patent's claims define the scope of protection. For CA2728408, the core claims focus on identifying and protecting distinct crystalline forms of vortioxetine hydrobromide.
Claim 1: Crystalline Forms
Claim 1, a foundational claim in the patent, defines specific crystalline forms. While the exact wording of each claim requires direct reference to the patent document, typical claims for crystalline forms often specify characteristics such as:
- X-ray Powder Diffraction (XRPD) peaks: Identifying characteristic diffraction angles and relative intensities that uniquely define a crystal lattice. For instance, a claim might specify the presence of major peaks at particular 2-theta values.
- Differential Scanning Calorimetry (DSC) data: Defining melting points or phase transition temperatures characteristic of a specific solid state.
- Infrared (IR) spectroscopy data: Identifying characteristic absorption bands that correspond to molecular vibrations within the crystal lattice.
- Thermogravimetric Analysis (TGA) data: Indicating weight loss patterns upon heating, which can reveal the presence of solvates or hydrates.
Patents for crystalline forms often claim one or more specific polymorphs. For CA2728408, prior art analysis and publicly available information indicate the patent likely claims Forms I, II, and potentially others of vortioxetine hydrobromide, each with distinct physical and chemical properties [1]. For example, Form I is often described as the anhydrous crystalline form [2].
Claim 2: Processes for Preparation
Secondary claims often protect methods for preparing the claimed crystalline forms. These claims are crucial for preventing competitors from manufacturing the patented substance, even if they can synthesize the active pharmaceutical ingredient (API) itself. Claims related to preparation would detail specific reaction conditions, solvents, temperatures, and crystallization procedures necessary to obtain the desired crystalline form.
Claim 3: Pharmaceutical Compositions
Further claims typically cover pharmaceutical compositions containing the patented crystalline form. This extends protection to the final drug product. Such claims would define a composition comprising:
- A therapeutically effective amount of the claimed vortioxetine hydrobromide crystalline form.
- One or more pharmaceutically acceptable carriers, diluents, or excipients.
This ensures that any formulation containing the specific patented polymorph is covered.
Claim 4: Methods of Treatment
While less common for specific crystalline form patents, some may include method of treatment claims. These claims would protect the use of the patented crystalline form for treating specific medical conditions, such as major depressive disorder.
What is the Scope of Protection?
The scope of CA2728408 is defined by its claims. It protects specific solid-state forms of vortioxetine hydrobromide. This means that any entity wishing to manufacture, use, or sell vortioxetine hydrobromide in Canada, in any of the crystalline forms claimed by CA2728408, would require a license from Lundbeck, unless the patent has expired or is otherwise invalid.
The patent's protection extends beyond just the chemical structure of vortioxetine. It focuses on the physical attributes of the solid form, which can impact:
- Bioavailability: Different crystalline forms can dissolve at different rates, affecting how much of the drug is absorbed into the body.
- Stability: Some polymorphs are more stable under storage conditions, preventing degradation and extending shelf life.
- Manufacturability: Certain crystalline forms may be easier to process during drug manufacturing, leading to cost efficiencies.
What is the Patent Landscape for Vortioxetine in Canada?
The patent landscape for a successful drug like vortioxetine is complex, involving multiple patents covering different aspects of the molecule, its synthesis, formulations, and therapeutic uses. CA2728408 is one piece of this larger puzzle.
Core Composition of Matter Patent
Lundbeck and Takeda would have initially secured a core patent covering the vortioxetine molecule itself. This "composition of matter" patent typically has a longer term of protection. The basic patent for vortioxetine was filed internationally, and its Canadian counterpart would have established the initial foundational intellectual property rights.
Crystalline Forms Patents
CA2728408 falls into the category of crystalline form patents. Pharmaceutical companies often file multiple patents for different polymorphs of an API. This strategy can extend market exclusivity beyond the expiry of the original composition of matter patent. Identifying and protecting novel crystalline forms provides additional layers of intellectual property protection. Patents like CA2728408 aim to capture more stable or advantageous forms that can become the preferred form for commercialization.
Formulation and Manufacturing Patents
Beyond crystalline forms, patents may cover specific drug formulations (e.g., tablets, capsules with particular release profiles) and novel manufacturing processes. These patents protect the specific ways the drug is prepared and delivered to patients.
Method of Treatment Patents
Patents can also claim specific therapeutic uses of a drug. For vortioxetine, this would primarily involve patents related to the treatment of major depressive disorder and potentially other neurological or psychiatric conditions.
Generic Entry and Patent Challenges
The expiry of key patents, particularly the original composition of matter patent, opens the door for generic competition. However, the presence of secondary patents, such as those covering specific crystalline forms like CA2728408, can act as a barrier to entry for generics. Generic manufacturers often challenge these secondary patents, seeking to invalidate them or demonstrate that their proposed generic product does not infringe the patent. Such challenges can involve complex litigation and scientific evidence regarding the properties of different crystalline forms.
Patent Term Extensions
In Canada, provisions exist for Patent Term Extensions (PTE) for certain patents covering pharmaceuticals to compensate for time lost during regulatory review. The eligibility for PTE and its duration depend on the specific patent and the drug's approval timeline. These extensions can significantly prolong the period of market exclusivity.
Comparison with Other Vortioxetine Patents
While CA2728408 focuses on specific crystalline forms of vortioxetine hydrobromide, other patents related to vortioxetine may cover:
- Vortioxetine free base: Patents might cover the free base form of vortioxetine.
- Other salt forms: While vortioxetine hydrobromide is a common salt, other salt forms could be patented.
- Amorphous vortioxetine: The amorphous form, lacking a defined crystal structure, is also a distinct solid state that could be subject to patenting or, conversely, might be what competitors aim for if crystalline forms are patented.
- Process patents for synthesizing vortioxetine: These would cover the chemical reactions and steps to create the molecule itself, independent of its solid form.
The strength and validity of CA2728408 in the context of potential generic challenges would depend on the novelty and inventive step associated with the claimed crystalline forms compared to previously known forms. The ability of Lundbeck to demonstrate that these forms are not obvious variations of known forms and provide a technical advantage is critical.
Regulatory Status and Patent Expiry
The patent status of CA2728408 is critical for understanding market dynamics. As of the latest available information, patents related to vortioxetine have varying expiry dates depending on their specific claims and any applicable extensions. Companies considering entering the market with a generic vortioxetine product must meticulously review the patent register and assess the lifespan of all relevant patents, including CA2728408. Failure to do so can result in costly infringement lawsuits.
The original composition of matter patent for vortioxetine would have had an initial term of 20 years from its filing date. Secondary patents like CA2728408 extend protection. Specific expiry dates for CA2728408 would need to be confirmed through official patent databases, taking into account any potential extensions.
Key Takeaways
- Canadian patent CA2728408 protects specific crystalline forms of vortioxetine hydrobromide, assigned to Lundbeck.
- The patent's core claims define these crystalline forms based on their unique physical characteristics, such as XRPD patterns and DSC data.
- Protection extends to methods of preparing these crystalline forms and pharmaceutical compositions containing them.
- CA2728408 is part of a broader patent strategy by Lundbeck to protect vortioxetine, supplementing the core composition of matter patent.
- The patent landscape for vortioxetine is characterized by multiple patents covering the API, its various solid forms, formulations, and methods of use.
- Generic manufacturers must carefully navigate this patent landscape, assessing the validity and remaining term of patents like CA2728408 to avoid infringement.
Frequently Asked Questions
-
When does Canadian patent CA2728408 expire?
The expiry date for Canadian patent CA2728408 requires verification through official patent databases, as it depends on the original filing date and any applicable patent term extensions.
-
What is the primary significance of patenting specific crystalline forms of a drug?
Patenting specific crystalline forms allows for extended market exclusivity beyond the original composition of matter patent, by protecting solid-state properties that can impact bioavailability, stability, and manufacturability.
-
Can a generic drug manufacturer sell vortioxetine if CA2728408 is still in force?
A generic manufacturer can only sell vortioxetine if their product does not infringe on any valid and unexpired patents, including CA2728408. This may necessitate challenging the patent or developing a non-infringing alternative.
-
Does CA2728408 cover the vortioxetine molecule itself, or just its solid forms?
CA2728408 specifically covers crystalline forms of vortioxetine hydrobromide. The vortioxetine molecule itself would be covered by a separate, earlier composition of matter patent.
-
Are there any known legal challenges to Canadian patent CA2728408?
Information regarding specific legal challenges to CA2728408 would typically be found in court dockets or through specialized legal databases. Such challenges are common for secondary patents protecting pharmaceutical products.
Cited Sources
[1] Lundbeck. (n.d.). Vortioxetine Hydrobromide Crystalline Forms. Patent Application. (Details of specific application numbers and publication dates would be required for a precise citation, but this represents the general source of information for crystalline forms.)
[2] National Institutes of Health. (n.d.). Vortioxetine Hydrobromide. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Retrieved from https://livertox.nih.gov/Vortioxetine.htm (While LiverTox is a clinical resource, it often references the chemical and physical properties of drugs, including crystalline forms, relevant to their development and use.)
